ASK REDCHAT ANYTHING ABOUT OUTLOOK THERAPEUTICS INC.
Outlook Therapeutics Inc. (NASDAQ: OTLK)
Listen to this Section
$0.84
+0.0252
(
+3.11% )
8.6M
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| ONS-5010 / LYTENAVA™ (bevacizumab-vikg)DetailsWet age-related macular degeneration , Eye diseaseBig Mover™Suspected Mover™Susp. Mover™ |
Phase 3 |
| ONS-5010 / LYTENAVA™ (bevacizumab-vikg)DetailsEye disease |
Phase 3 |
| ONS-5010 / LYTENAVA™ (bevacizumab-vikg)DetailsDiabetes, Eye disease , BK virus, Adenovirus, Epstein-Barr virus, Human herpesvirus 6, Cytomegalovirus, Diabetic macular edema |
Phase 3 |
| ONS-5010 / LYTENAVA™ (bevacizumab-vikg)DetailsEye disease , Wet age-related macular degenerationBig Mover™Suspected Mover™Susp. Mover™ |
Phase 3 |
Market Data
|
| Open |
$0.84 |
| Previous Close |
$0.81 |
| Volume |
8.6M |
| Market Cap |
$120.33M |
| Day Range |
$0.79 - $0.89 |
| 52 Week Range |
$0.16 - $3.39 |
| Shares Outstanding |
148.59M |
| Change % |
+3.11% |
| Net Change |
▲ 0.0252 |
| Insider Ownership |
-0.04% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| IPO Year | 2016 |
| Country | United States |
| Underwriter | IPO Intelligence Only |
Insider Ownership Transactions
Total Amount Purchased:
-4,769,613.29
| Date |
Type |
Amount Purchased |
Purchaser |
| 2024-09-30 |
Buy |
5000.00 |
KENYON LAWRENCE A |
| 2024-04-17 |
Buy |
714286.00 |
Syntone Ventures LLC |
| 2024-03-29 |
Buy |
1881.71 |
Haddadin Yezan Munther |
| 2024-03-22 |
Sale |
-12500.00 |
KENYON LAWRENCE A |
| 2024-03-22 |
Sale |
-25000.00 |
Evanson Jeff |
| 2024-03-22 |
Sale |
-455000.00 |
TRENARY C RUSSELL III |
| 2024-03-20 |
Sale |
-2305714.00 |
Sukhtian Ghiath M. |
| 2024-03-11 |
Buy |
62484.00 |
Evanson Jeff |
| 2024-03-08 |
Sale |
-94441.00 |
Auffarth Gerd |
| 2024-03-08 |
Sale |
-94441.00 |
Huang Andong |